Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (13209)
All Articles published online
|
Publishing Process of This Article
|
Jan 14, 2016 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Matsuoka T, Yashiro M. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. World J Gastroenterol 2016; 22(2): 776-789 [PMID: 26811624 DOI: 10.3748/wjg.v22.i2.776] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i2/776.htm |
| Number | Citing Articles |
| 1 |
Mark B. Ulanja, Alastair E. Moody, Bryce D. Beutler, Daniel Antwi-Amoabeng, Ganiyu A. Rahman, Olatunji B. Alese. Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival. Oncotarget 2022; 13(1): 828 doi: 10.18632/oncotarget.28242
|
| 2 |
Ahmed E. Elsawi, Mai I. Shahin, Hager A. Elbendary, Tarfah Al-Warhi, Fatma E. Hassan, Wagdy M. Eldehna. 1,2,4-Triazole-Tethered Indolinones as New Cancer-Fighting Small Molecules Targeting VEGFR-2: Synthesis, Biological Evaluations and Molecular Docking. Pharmaceuticals 2024; 17(1): 81 doi: 10.3390/ph17010081
|
| 3 |
Huaqing Shi, Zhou Chen, Shi Dong, Ru He, Yan Du, Zishun Qin, Wence Zhou. A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study. BMC Gastroenterology 2022; 22(1) doi: 10.1186/s12876-022-02362-2
|
| 4 |
Chandra Diwakarla, Katherine Hannan, Nadine Hein, Desmond Yip. Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options. World Journal of Gastroenterology 2017; 23(13): 2276-2285 doi: 10.3748/wjg.v23.i13.2276
|
| 5 |
Qi Liu, Hongyu Zhao, Yu Guo, Kai Zhang, Fengjia Shang, Tongjun Liu, Mihajlo Jakovljevic. Bioinformatics-Based Analysis: Noncoding RNA-Mediated COL10A1 Is Associated with Poor Prognosis and Immune Cell Infiltration in Pancreatic Cancer. Journal of Healthcare Engineering 2022; 2022: 1 doi: 10.1155/2022/7904982
|
| 6 |
Sinan Lu, Tianyu He, Yuan Zhang, Bo Zhou, Qiyi Zhang, Sheng Yan. The MyD88 inhibitor, ST2825, induces cell cycle arrest and apoptosis by suppressing the activation of the NF‑κB/AKT1/p21 pathway in pancreatic cancer. Oncology Reports 2023; 50(2) doi: 10.3892/or.2023.8585
|
| 7 |
Yumi Kim, Kang-Hoon Kim, In-Seung Lee, Ji Young Park, Yun-Cheol Na, Won-Seok Chung, Hyeung-Jin Jang. Apoptosis and G2/M cell cycle arrest induced by a timosaponin A3 from Anemarrhena asphodeloides Bunge on AsPC-1 pancreatic cancer cells. Phytomedicine 2019; 56: 48 doi: 10.1016/j.phymed.2018.08.006
|
| 8 |
Sharavan Ramachandran, Sanjay K. Srivastava. Repurposing Pimavanserin, an Anti-Parkinson Drug for Pancreatic Cancer Therapy. Molecular Therapy - Oncolytics 2020; 19: 19 doi: 10.1016/j.omto.2020.08.019
|
| 9 |
Xifeng Xu, Qiong Wu, Zhen Wang, Song Zheng, Ke Ge, Changku Jia. Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer. Clinical and Experimental Medicine 2019; 19(1): 149 doi: 10.1007/s10238-018-0540-3
|
| 10 |
Oliver A. Kent, Maria-Jose Sandi, Robert Rottapel. Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition. Small GTPases 2019; 10(6): 441 doi: 10.1080/21541248.2017.1337545
|
| 11 |
Asuman Argon, Özden Öz, TuluAyata Kebat. Evaluation and prognostic significance of tumor budding in pancreatic ductal adenocarcinomas. Indian Journal of Pathology and Microbiology 2023; 66(1): 38 doi: 10.4103/ijpm.ijpm_905_21
|
| 12 |
Steven N. Hochwald, William G. Cance, Elena Kurenova. Encyclopedia of Cancer. 2014; : 3421 doi: 10.1007/978-3-662-46875-3_4358
|
| 13 |
Anabela Barros, Catarina Pulido, Manuela Machado, Maria Brito, Nuno Couto, Olga Sousa, Sónia Melo, Hélder Mansinho. Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). International Journal of Oncology 2021; 59(6) doi: 10.3892/ijo.2021.5290
|
| 14 |
Federica Eduati, Patricia Jaaks, Jessica Wappler, Thorsten Cramer, Christoph A Merten, Mathew J Garnett, Julio Saez‐Rodriguez. Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies. Molecular Systems Biology 2020; 16(2) doi: 10.15252/msb.20188664
|
| 15 |
Silviu Stanciu, Florentina Ionita-Radu, Constantin Stefani, Daniela Miricescu, Iulia-Ioana Stanescu-Spinu, Maria Greabu, Alexandra Ripszky Totan, Mariana Jinga. Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects. International Journal of Molecular Sciences 2022; 23(17): 10132 doi: 10.3390/ijms231710132
|
| 16 |
Mehdi El Amrani, François Corfiotti, Matthieu Corvaisier, Romain Vasseur, Maxence Fulbert, Cécile Skrzypczyk, Anne‐Claire Deshorgues, Viviane Gnemmi, David Tulasne, Fatima Lahdaoui, Audrey Vincent, François‐René Pruvot, Isabelle Van Seuningen, Guillemette Huet, Stéphanie Truant. Gemcitabine‐induced epithelial‐mesenchymal transition‐like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal‐like phenotype. Molecular Carcinogenesis 2019; 58(11): 1985 doi: 10.1002/mc.23090
|
| 17 |
Jiangang Zhao, Jiahui Li, Hans A. Schlößer, Felix Popp, Marie Christine Popp, Hakan Alakus, Karl-Walter Jauch, Christiane J. Bruns, Yue Zhao. Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer. Stem Cells International 2017; 2017: 1 doi: 10.1155/2017/6012810
|
| 18 |
E. A. Bykova, N. A. Falaleeva, L. Yu. Grivtsova. PANCREATIC CANCER, CURRENT THERAPEUTIC APPROACHES AND POSSIBLE PROSPECTS. Russian Journal of Biotherapy 2020; 19(4): 18 doi: 10.17650/1726-9784-2020-19-4-18-28
|
| 19 |
Nilabja Sikdar, Akash Bararia, Ashmita Dutta, Sudeep Banerjee. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. 2022; : 1 doi: 10.1007/978-981-16-1247-3_77-1
|
| 20 |
Xiaochen Wu, Qiqi Li, Fan Zhang, Lijun Wang, Jun Wang, Junting Fan, Guohu Di, Chuanlong Guo. Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells. Food and Chemical Toxicology 2021; 147: 111892 doi: 10.1016/j.fct.2020.111892
|
| 21 |
Mubin Tarannum, Juan L. Vivero-Escoto. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. Advanced Drug Delivery Reviews 2022; 187: 114357 doi: 10.1016/j.addr.2022.114357
|
| 22 |
Han-xiang Zhan, Bin Zhou, Yu-gang Cheng, Jian-wei Xu, Lei Wang, Guang-yong Zhang, San-yuan Hu. Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology. Cancer Letters 2017; 392: 83 doi: 10.1016/j.canlet.2017.01.041
|
| 23 |
Wen Li, Fang Li, Yang Zhang, Hongtao Ren, Xing Bao, Zhongwei Wang, Yali Wang. X-Linked Inhibitor of Apoptosis Protein (XIAP)-Loaded Magnetic Mesoporous Silica Nanoparticles Incorporated with miR-233 to Improve Radio Sensitization of Cervical Cancer Cells and Promote Apoptosis. Journal of Biomedical Nanotechnology 2022; 18(3): 747 doi: 10.1166/jbn.2022.3281
|
| 24 |
Bhaskar Venkata Kameswara Subrahmanya Lakkakula, Batoul Farran, Saikrishna Lakkakula, Sujatha Peela, Nagendra Sastry Yarla, Pallaval Veera Bramhachari, Mohammad Amjad Kamal, Madhu Sudhana Saddala, Ganji Purnachandra Nagaraju. Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles. Seminars in Cancer Biology 2019; 56: 149 doi: 10.1016/j.semcancer.2018.09.011
|
| 25 |
Maud-Emmanuelle Gilles, Federica Maione, Mélissande Cossutta, Gilles Carpentier, Laure Caruana, Silvia Di Maria, Claire Houppe, Damien Destouches, Ksenya Shchors, Christopher Prochasson, Fabien Mongelard, Simona Lamba, Alberto Bardelli, Philippe Bouvet, Anne Couvelard, José Courty, Enrico Giraudo, Ilaria Cascone. Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature. Cancer Research 2016; 76(24): 7181 doi: 10.1158/0008-5472.CAN-16-0300
|
| 26 |
Allison Solanki, Diana King, Guillaume Thibault, Lei Wang, Summer L. Gibbs, Irina V. Lebedeva. Quantification of fluorophore distribution and therapeutic response in matched in vivo and ex vivo pancreatic cancer model systems. PLOS ONE 2020; 15(2): e0229407 doi: 10.1371/journal.pone.0229407
|
| 27 |
Elzbieta Nowara, Joanna Huszno. Masitinib plus gemcitabine for personalized treatment of PDAC patients with overexpression of ACOX1. Expert Review of Precision Medicine and Drug Development 2016; 1(6): 479 doi: 10.1080/23808993.2016.1257911
|
| 28 |
Rosalba Florio, Serena Veschi, Viviana di Giacomo, Sara Pagotto, Simone Carradori, Fabio Verginelli, Roberto Cirilli, Adriano Casulli, Antonino Grassadonia, Nicola Tinari, Amelia Cataldi, Rosa Amoroso, Alessandro Cama, Laura De Lellis. The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer. Cancers 2019; 11(12): 2042 doi: 10.3390/cancers11122042
|
| 29 |
Kay K. Myo Min, Charlie B. Ffrench, Claire F. Jessup, Mia Shepherdson, Savio George Barreto, Claudine S. Bonder. Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities. Cancers 2023; 15(8): 2354 doi: 10.3390/cancers15082354
|
| 30 |
JingJing Duan, Wen Yue, JianYu E, Jyoti Malhotra, Shou-en Lu, Jun Gu, Feng Xu, Xiang-Lin Tan. In vitro comparative studies of resveratrol and triacetylresveratrol on cell proliferation, apoptosis, and STAT3 and NFκB signaling in pancreatic cancer cells. Scientific Reports 2016; 6(1) doi: 10.1038/srep31672
|
| 31 |
Steven N. Hochwald, William G. Cance, Elena Kurenova. Encyclopedia of Cancer. 2014; : 1 doi: 10.1007/978-3-642-27841-9_4358-4
|
| 32 |
Taishi Higashi, Tetsuya Kogo, Nana Sato, Tatsunori Hirotsu, Shogo Misumi, Hideaki Nakamura, Daisuke Iohara, Risako Onodera, Keiichi Motoyama, Hidetoshi Arima. Efficient Anticancer Drug Delivery for Pancreatic Cancer Treatment Utilizing Supramolecular Polyethylene-Glycosylated Bromelain. ACS Applied Bio Materials 2020; 3(5): 3005 doi: 10.1021/acsabm.0c00070
|
| 33 |
Matthew Loft, Belinda Lee, Jeanne Tie, Peter Gibbs. Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma. Journal of Personalized Medicine 2019; 9(3): 37 doi: 10.3390/jpm9030037
|
| 34 |
Lijun Wang, Shuhong Zhang, Xuemin Yu, Chuanlong Guo. Novel Poly(ADP-ribose) Polymerase-1 Inhibitor DDHCB Inhibits Proliferation of BRCA Mutant Breast Cancer Cell In Vitro and In Vivo through a Synthetic Lethal Mechanism. Chemical Research in Toxicology 2020; 33(7): 1874 doi: 10.1021/acs.chemrestox.0c00087
|
| 35 |
Nilabja Sikdar, Akash Bararia, Ashmita Dutta, Sudeep Banerjee. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. 2022; : 1525 doi: 10.1007/978-981-16-5422-0_77
|
| 36 |
Bayarmaa Mandzhieva, Rima Shobar, Anum Jalil, Hammad Zafar, Mamoon Ur Rashid, Ranjeet Kumar, Akash Khetpal, Sarfraz Ahmad. Phytochemicals Targeting Tumor Microenvironment in Gastrointestinal Cancers. 2020; : 223 doi: 10.1007/978-3-030-48405-7_11
|
| 37 |
Jasmeet Kaur, Paramveer Singh, Thomas Enzler, Vaibhav Sahai. Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials. Expert Opinion on Emerging Drugs 2021; 26(2): 103 doi: 10.1080/14728214.2021.1905795
|
| 38 |
Wei Hu, Xuefeng Jia, Yanfang Gao, Qiujie Zhang. Chaetospirolactone reverses the apoptotic resistance towards TRAIL in pancreatic cancer. Biochemical and Biophysical Research Communications 2018; 495(1): 621 doi: 10.1016/j.bbrc.2017.10.144
|
| 39 |
Seyoung Park, Hao Xu, Hongyu Zhao. Integrating Multidimensional Data for Clustering Analysis With Applications to Cancer Patient Data. Journal of the American Statistical Association 2021; 116(533): 14 doi: 10.1080/01621459.2020.1730853
|
| 40 |
Ozden Oz, Asuman Argon, TuluAyata Kebat, Ozlem Ozdemir, Savas Yakan. Prognostic significance of ımmunhistochemical axl expression in pancreas ductal adenocarcinomas. Indian Journal of Pathology and Microbiology 2023; 66(3): 533 doi: 10.4103/ijpm.ijpm_1002_21
|
| 41 |
Dinesh Kumar, Pranjal Sarma, Manika P. Bhadra, Anjana D. Tangutur. Impact of Hybrid-polar Histone Deacetylase Inhibitor m-Carboxycinnamic Acid bis-Hydroxyamide on Human Pancreatic Adenocarcinoma Cells. Anti-Cancer Agents in Medicinal Chemistry 2019; 19(6): 750 doi: 10.2174/1871520619666190101115034
|
| 42 |
鹏 闫. Advances in Diagnosis and Treatment of Pancreatic Cancer. Hans Journal of Surgery 2020; 9(02): 5 doi: 10.12677/HJS.2020.92002
|
| 43 |
Mohamed Islam Delma. Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?. Cureus 2020; doi: 10.7759/cureus.10909
|
| 44 |
Shuyi Li, Mengke Niu, Wenying Deng, Ning Li, Chen Wei, Suxia Luo. Anlotinib is effective in the treatment of advanced pancreatic cancer: a case report. Anti-Cancer Drugs 2022; 33(1): e558 doi: 10.1097/CAD.0000000000001173
|